Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

NCT05400109 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: CASE2422
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 3

Brief Summary

This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.

Conditions

Non Hodgkin Lymphoma

Keywords

UF-KURE19; CD19 CAR-T cells; Non Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (6)

• Phase 1: Recommended dose(s) of UF-KURE19 CAR-T Cells

  Safety will be assessed by the number of DLT experienced at the target dose which is hypothesized to be less than 33%.

  Up to 28 days after treatment

• Phase 1: Toxicities associated with the target dose of UF-KURE19 CAR-T Cells

  Toxicities will be reported as specific adverse events as a result of the target dose of UF-KURE19 CAR-T Cells. An adverse event (AE) is any unfavorable or unintended event, physical or psychological, associated with a research study, which causes harm or injury to a research participant as a result of the participant's involvement in a research study.

  Up to 12 months after treatment

• Phase 1b: Toxicities associated with the target dose of UFKURE19 in patients with Relapsed or Refractory Large B-cell Lymphoma (LBCL).

  Up to 12 months after treatment

• Phase 1b: Complete response rate (CRR) with UF-KURE19 in patients with Relapsed or Refractory LBCL.

  Up to 12 months after treatment

• Phase 1b: Objective response rate (ORR, CR + PR) with UF-KURE19 in patients with Relapsed or Refractory LBCL.

  Up to 12 months after treatment

• Phase 1b: CRR in double/triple hit lymphoma (DHL/THL) patients treated with first-line standard of care chemoimmunotherapy PLUS early intervention of UFKURE19.

  Up to 12 months after treatment

Secondary Outcomes (8)

• Phase 1: Success rate of semi-automated CAR-T manufacturing process

  Up to 2 weeks after culture of UF-KURE19 CAR-T cells

• Phase 1: Objective response rates per Lugano Revised Response Criteria for Malignant Lymphoma after treatment with UF-KURE19 in patients with relapsed or refractory non-Hodgkin lymphoma

  Up to 12 months after treatment

• Phase 1: Complete response rates per Lugano Revised Response Criteria for Malignant Lymphoma after treatment with UF-KURE19 in patients with relapsed or refractory non-Hodgkin lymphoma

  Up to 12 months after treatment

• Phase 1b cohort of Relapsed or Refractory LBCL: duration of response in patients treated with UF-KURE19

  Up to 12 months after treatment

• Phase 1b cohort of Relapsed or Refractory Large B cell Lymphoma(LBCL): Overall survival in patients treated with UF-KURE19

  Up to 12 months after treatment

Study Arms (1)

UF-KURE19 CAR-T cell infusion

EXPERIMENTAL

The safety and manufacturing feasibility of UF-KURE19 will be determined with up to 10 patients being enrolled. Lymphodepleting therapy will begin on Days -4 to -2 with each weight category of participants receiving 30mg/m2/IV of Fludarabine and 500mg/m2/IV of Cyclophosphamide regardless of the level of UF-KURE19 CAR-T cell dosing. Dosing: Participants greater than or equal to 50 kg: * Level -1: 10 x 10\^6 UF-KURE19 CAR-T Cell Dose (CAR positive cells) * Level 1 : 17.5 x 10\^6 UF-KURE19 CAR-T Cell Dose Participants less than 50 kg: * Level -1: 6.5 x 10\^6 UF-KURE19 CAR-T Cell Dose * Level 1: 11.5 x 10\^6 UF-KURE19 CAR-T Cell Dose

Biological: UF-KURE19 CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide

Interventions

UF-KURE19 CAR-T cells BIOLOGICAL

UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved

UF-KURE19 CAR-T cell infusion

Fludarabine DRUG

Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.

Also known as: Fludara®, Fludarabine Phosphate

UF-KURE19 CAR-T cell infusion

Cyclophosphamide DRUG

The mechanism of action is thought to involve cross-linking of tumor cell DNA

Also known as: Cytoxan ®, Endoxan®, Neosar®, Procytox®, Revimmune®, Cycloblastin®

UF-KURE19 CAR-T cell infusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged 18 years or older.
• Participants must have histologically confirmed, CD19 positive (by IHC or flow cytometry) NHL that meets at least one of the following treatment indications.
• Relapsed after 2 or more lines of chemotherapy, (or)
• Refractory to chemotherapy, defined as: Progressive disease while receiving last chemotherapy, or Persistent disease after first line chemotherapy treatment with curative intent or stable disease lasting ≤6 months after last chemotherapy, or relapse within 6 months of last chemotherapy, or disease progression or relapse ≤12 months after prior autologous stem cell transplant, (or)
• Relapsed disease that is ineligible to receive hematopoietic stem cell transplantation due to comorbidities or age or patient preference.
• ECOG Performance status ≤ 2.
• At least one measurable lesion according to Lugano Revised Response Criteria for Malignant Lymphoma.
• Minimum of 2 weeks since prior radiation therapy or systemic therapy to treat malignancy at the time of leukapheresis.
• Total bilirubin ≤ 1.5X institutional upper limit of normal.
• AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal.
• Calculated creatinine clearance ≥ 30mL/min estimated by the Cockcroft - Gault formula.
• Cardiac ejection fraction of ≥45%, and no more than trivial (or trace, minimal or mild) pericardial effusion, as determined by an echocardiogram.
• Adequate pulmonary function, defined as ≤ Grade 1 dyspnea (unless considered secondary to lymphoma) and oxygen saturation (SaO2) ≥ 92% on room air. If pulmonary function tests (PFTs) are performed based on the clinical judgment of the treating physician, patients with forced expiratory volume in 1 second (FEV1)
• ≥ 50% of predicted and diffusing capacity for carbon monoxide (DLCO) (corrected for hemoglobin) of ≥ 40% of predicted will be eligible.
• Participants (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

• The presence of any of the following will exclude a subject from study enrollment:
• Autologous stem cell transplant within 6 weeks of informed consent.
• History of allogeneic hematopoietic stem cell transplantation.
• Active central nervous system or leptomeningeal involvement by lymphoma. Subjects with untreated brain metastases/CNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal CASE 2422 Page 37 Version 13 02.03.2025 involvement must be in a documented remission by CSF evaluation and contrastenhanced MRI imaging for at least 90 days prior to registration.
• Second active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast).
• Less than 28 days elapsed between prior treatment with investigational agent(s) and leukapheresis.
• New York Heart Association class III-IV congestive heart failure. Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration.
• Known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness.
• Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
• Evidence of myelodysplastic syndrome or cytogenetic abnormality indicative of myelodysplasia on the most recent bone marrow biopsy prior to initiation of therapy.
• Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded).
• Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
• Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
• History of active autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of systemic immunosuppressive medications other than low dose steroids \[i.e. maximum of 15mg prednisone equivalent\] within the last 6 months.
• Circulating malignant B cells in peripheral blood detected by complete blood count at the time of subject enrollment.

Sponsors & Collaborators

• David Wald: lead

Study Sites (3)

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States

Location

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Cleveland, Ohio, 44106, United States

Location

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Interventions

fludarabine; fludarabine phosphate; Cyclophosphamide

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds

Study Officials

• Changchun Deng, MD, PhD

  University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: IND Holder

Study Record Dates

• First Submitted: May 27, 2022
• First Posted: June 1, 2022
• Study Start: April 26, 2023
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: May 5, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)